Find Elobixibat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 439087-18-0, Azd7806, Azd-7806, 865uek4ejc, A-3309, Glycine, (2r)-n-(2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-
Molecular Formula
C36H45N3O7S2
Molecular Weight
695.9  g/mol
InChI Key
XFLQIRAKKLNXRQ-UUWRZZSWSA-N
FDA UNII
865UEK4EJC

Elobixibat
Elobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation.
1 2D Structure

Elobixibat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-16,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid
2.1.2 InChI
InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
2.1.3 InChI Key
XFLQIRAKKLNXRQ-UUWRZZSWSA-N
2.1.4 Canonical SMILES
CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)NC(C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC
2.1.5 Isomeric SMILES
CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)C1)OCC(=O)N[C@H](C3=CC=CC=C3)C(=O)NCC(=O)O)SC)C4=CC=CC=C4)CCCC
2.2 Other Identifiers
2.2.1 UNII
865UEK4EJC
2.3 Synonyms
2.3.1 MeSH Synonyms

1. A3309

2.3.2 Depositor-Supplied Synonyms

1. 439087-18-0

2. Azd7806

3. Azd-7806

4. 865uek4ejc

5. A-3309

6. Glycine, (2r)-n-(2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-

7. Goofice

8. (r)-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetyl)glycine

9. 2-[[(2r)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1lambda6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic Acid

10. Elobixibat [inn]

11. Azd 7806

12. Elobixibat [usan:inn]

13. Unii-865uek4ejc

14. Ajg533

15. Elobixibat [mi]

16. Elobixibat (usan/inn)

17. Elobixibat [usan]

18. A 3309

19. Elobixibat [who-dd]

20. Gtpl9996

21. Schembl1183501

22. Chembl3039515

23. Bdbm77088

24. Dtxsid00195985

25. Ex-a5983

26. Db12486

27. Hy-15790

28. Cs-0009139

29. J3.548.450g

30. D10796

31. Us9694018, 14

32. Q5367035

33. ((2r)-2-(2-((3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1h-1.lambda.6,5-benzothiazepin-8-yl)oxy)acetamido)-2-phenylacetamido)acetic Acid

34. 2-[[(2r)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydrobenzo[b][1,4]thiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic Acid

35. Glycine, (2r)-n-(((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 695.9 g/mol
Molecular Formula C36H45N3O7S2
XLogP37.1
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count9
Rotatable Bond Count16
Exact Mass695.26989313 g/mol
Monoisotopic Mass695.26989313 g/mol
Topological Polar Surface Area176 Ų
Heavy Atom Count48
Formal Charge0
Complexity1140
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of chronic constipation


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37340

Submission : 2022-10-19

Status : Active

Type : II

Metrochem
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

ELOBIXIBAT MONOHYDRATE

NDC Package Code : 42765-052

Start Marketing Date : 2023-01-24

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (2kg/2kg)

Marketing Category : BULK INGREDIENT

Metrochem
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

ChemExpress

China
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

Flag China
Digital Content Digital Content

Elobixibat

About the Company : Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADC...

Founded in 2006, ChemExpress provides CRO and CDMO services to pharmaceutical and biotech companies. The company supports small molecules, biologics, and new modalities such as ADCs/XDCs, peptides, and PROTACs. Its capabilities cover research, development, manufacturing, and supply of regulatory starting materials, building blocks, intermediates, reference compounds, APIs, and drug products. ChemExpress supports projects from early drug discovery through process development and commercialization. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Elobixibat

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

03

IPPE
Not Confirmed
arrow
arrow
IPPE
Not Confirmed

Elobixibat

About the Company : Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is focused on offering co...

Ceyone Life Sciences specializes in providing research-oriented chemistry services and manufacturing niche chemicals, intermediates, and APIs. The company is focused on offering comprehensive R&D services to meet the global needs of clients while ensuring environmental sustainability and compliance with international regulatory standards. Their goal is to be a leading provider of innovative solutions in the field of specialty chemicals and pharmaceuticals.
blank

04

IPPE
Not Confirmed
arrow
arrow
IPPE
Not Confirmed

Elobixibat

About the Company : Established in 1997, the PRECISE Group is a respected pharmaceutical company in India with an annual turnover of USD 40 million. Backed by a skilled regulatory team, a dedicated fo...

Established in 1997, the PRECISE Group is a respected pharmaceutical company in India with an annual turnover of USD 40 million. Backed by a skilled regulatory team, a dedicated formulation and development unit, and over 100 professionals, PRECISE has emerged as a one-stop solution for APIs, intermediates, and finished formulations. Leveraging our core strengths, we continue to strengthen our presence in the global market.
blank

05

IPPE
Not Confirmed
arrow
arrow
IPPE
Not Confirmed

Elobixibat

About the Company : Viruj Pharmaceuticals, an India-based company with a global presence, aims to develop & market complex, technology-driven APIs. It offers contract API manufacturing for innovative ...

Viruj Pharmaceuticals, an India-based company with a global presence, aims to develop & market complex, technology-driven APIs. It offers contract API manufacturing for innovative companies globally, & APIs for generic companies. Viruj Pharmaceuticals adheres to quality systems defined in Schedule M, Schedule L, ICH Q7 & TRS guidelines & leads in process validation, cleaning validation, analytical method transfers & process technology. It ensures GMP compliance at its facility. Viruj seeks to develop APIs via continuous Flow Technology & has invested in the requisite infrastructure for developing APIs using Flow Chemistry techniques.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655058600,"product":"ELOBIXIBAT MONOHYDRATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"SYNGENE INTERNATIONAL LTD UNIT III BLOCK S 14","supplierCountry":"INDIA","foreign_port":"NARITA APT\/TOKYO","customer":"EA PHARMA CO LTD 103 1 USHISHIMIZU SHIRASAKA","customerCountry":"JAPAN","quantity":"207.00","actualQuantity":"207","unit":"KGS","unitRateFc":"4711.5","totalValueFC":"960078.5","currency":"USD","unitRateINR":361839.6183574879,"date":"13-Jun-2022","totalValueINR":"74900801","totalValueInUsd":"960078.5","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"4002835","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1687717800,"product":"ELOBIXIBAT MONOHYDRATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"SYNGENE INTERNATIONAL LTD UNIT III BLOCK S 14","supplierCountry":"INDIA","foreign_port":"NARITA APT\/TOKYO","customer":"EA PHARMA CO LTD","customerCountry":"JAPAN","quantity":"104.00","actualQuantity":"104","unit":"KGS","unitRateFc":"4534.3","totalValueFC":"466715.2","currency":"USD","unitRateINR":368867.85576923075,"date":"26-Jun-2023","totalValueINR":"38362257","totalValueInUsd":"466715.2","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"4003503","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716748200,"product":"ELOBIXIBAT MONOHYDRATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"","supplier":"SYNGENE INTERNATIONAL LTD UNIT III BLOCK S 14","supplierCountry":"INDIA","foreign_port":"FUKUSHIMA","customer":"EA PHARMA CO LTD","customerCountry":"JAPAN","quantity":"53.00","actualQuantity":"53","unit":"KGS","unitRateFc":"6082.1","totalValueFC":"319626.9","currency":"USD","unitRateINR":502683.71698113205,"date":"27-May-2024","totalValueINR":"26642237","totalValueInUsd":"319626.9","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"4002602","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1724437800,"product":"ELOBIXIBAT (AMORPHOUS) IHS (PHARMACEUTICAL RAW MATERIALS)","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TOKYO - NARITA","customer":"NIPPON CHEMIPHAR CO LTD","customerCountry":"JAPAN","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"45000","totalValueFC":"8801.2","currency":"USD","unitRateINR":3691166.1499999999,"date":"24-Aug-2024","totalValueINR":"738233.23","totalValueInUsd":"8801.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"3466859","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731349800,"product":"FINE ORGANIC COMPOUNDSELOBIXIBAT MONOHYDRATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"N\/A","supplier":"SYNGENE INTERNATIONAL LTD","supplierCountry":"INDIA","foreign_port":"FUKUSHIMA, 07","customer":"EA PHARMA CO LTD","customerCountry":"JAPAN","quantity":"104.73","actualQuantity":"104.73","unit":"KGS","unitRateFc":"6126","totalValueFC":"634443.3","currency":"USD","unitRateINR":511214.69999045163,"date":"12-Nov-2024","totalValueINR":"53539515.53","totalValueInUsd":"634443.3","indian_port":"Biocon-SEZ","hs_no":"29420090","bill_no":"5534224","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1735583400,"product":"ELOBIXIBAT HYDRATE PHARMACEUTICAL RAW MATERIALS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE SOUTHEAST BANK PLC","customerCountry":"BANGLADESH","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"11500","totalValueFC":"22718.6","currency":"USD","unitRateINR":965187.5,"date":"31-Dec-2024","totalValueINR":"1930375","totalValueInUsd":"22718.6","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"6916191","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736361000,"product":"ELOBIXIBAT HYDRATE IHS PHARMACEUTICAL RAW MATERIALS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"UTOPIA PHARMACEUTICALS","customerCountry":"EGYPT","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"12500","totalValueFC":"61418.6","currency":"USD","unitRateINR":1059215.7619999999,"date":"09-Jan-2025","totalValueINR":"5296078.81","totalValueInUsd":"61418.6","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7142198","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1736706600,"product":"ELOBIXIBAT HYDRATE PHARMACEUTICAL RAW MATERIALS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"MERCANTILE BANK PLC","customerCountry":"BANGLADESH","quantity":"0.35","actualQuantity":"0.35","unit":"KGS","unitRateFc":"18000","totalValueFC":"6112.8","currency":"USD","unitRateINR":1505994.2857142859,"date":"13-Jan-2025","totalValueINR":"527098","totalValueInUsd":"6112.8","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"7247565","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1746037800,"product":"ELOBIXIBAT HYDRATE PHARMACEUTICAL RAW MATERIALS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DHAKA","customer":"TO THE SOUTHEAST BANK PLC","customerCountry":"BANGLADESH","quantity":"7.00","actualQuantity":"7","unit":"KGS","unitRateFc":"11500","totalValueFC":"79916.9","currency":"USD","unitRateINR":972710.71428571432,"date":"01-May-2025","totalValueINR":"6808975","totalValueInUsd":"79916.9","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"1433865","productDescription":"API","marketType":"","country":"BANGLADESH","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753813800,"product":"ELOBIXIBAT HYDRATE PHARMACEUTICAL RAW MATERIALS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"UTOPIA PHARMACEUTICALS","customerCountry":"EGYPT","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"12500","totalValueFC":"61647.7","currency":"USD","unitRateINR":1061152.6880000001,"date":"30-Jul-2025","totalValueINR":"5305763.44","totalValueInUsd":"61647.7","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4010417","productDescription":"API","marketType":"","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1758479400,"product":"ELOBIXIBAT MONOHYDRATE","address":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3","city":"N\/A","supplier":"SYNGENE INTERNATIONAL LTD","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"EA PHARMA CO LTD","customerCountry":"JAPAN","quantity":"97.88","actualQuantity":"97.88","unit":"KGS","unitRateFc":"5960","totalValueFC":"575969.1","currency":"USD","unitRateINR":519414,"date":"22-Sep-2025","totalValueINR":"50840242.32","totalValueInUsd":"575969.1","indian_port":"Biocon-SEZ","hs_no":"29342090","bill_no":"5523900","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Biocon-SEZ","supplierAddress":"BIOCON SEZ, BIOCON PARK,PLOT NO.2 3, N\/A","customerAddress":""}]
13-Jun-2022
22-Sep-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 09, 2023

blank

01

Synmosa

Taiwan
arrow
IPPE
Not Confirmed

Synmosa

Taiwan
arrow
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 09, 2023

blank

Details:

Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Goofice

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 18, 2020

blank

02

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.

Product Name : Goofice

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 18, 2020

blank

Details:

These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intrahepatic cholestasis.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Goofice

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Hercules Capital

Deal Size: $105.0 million Upfront Cash: $10.0 million

Deal Type: Financing June 09, 2020

blank

03

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : These funding arrangements with new and existing partners provide the company additional flexibility and cash runway into the beginning of 2022, past the planned approval and commercial launch of odevixibat for the treatment of progressive familial intra...

Product Name : Goofice

Product Type : Miscellaneous

Upfront Cash : $10.0 million

June 09, 2020

blank

Details:

Trial enrolled 47 patients, and is designed to assess the safety and efficacy of a once-daily 5mg dose of elobixibat over 16 weeks in adult patients across 10 U.S. sites with biopsy-confirmed NASH.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Goofice

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2020

blank

04

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Trial enrolled 47 patients, and is designed to assess the safety and efficacy of a once-daily 5mg dose of elobixibat over 16 weeks in adult patients across 10 U.S. sites with biopsy-confirmed NASH.

Product Name : Goofice

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 10, 2020

blank
  • Development Update

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.


Lead Product(s): Elobixibat,Cholestyramine

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: EA Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 21, 2020

blank

05

Yokohama City University

Country
arrow
IPPE
Not Confirmed

Yokohama City University

Country
arrow
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 21, 2020

blank
  • Development Update

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 05, 2019

blank

06

Albireo

Country
arrow
IPPE
Not Confirmed

Albireo

Country
arrow
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 05, 2019

blank

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 19, 2015

blank

07

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Constipation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 19, 2015

blank

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 10, 2013

blank

08

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 10, 2013

blank

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 16, 2013

blank

09

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 16, 2013

blank

Details:

Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.


Lead Product(s): Elobixibat,Inapplicable

Therapeutic Area: Gastroenterology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 09, 2013

blank

10

IPPE
Not Confirmed
IPPE
Not Confirmed

Details : Elobixibat is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Constipation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 09, 2013

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATE SUPPLIERS

read-more
read-more

01

Scinvapharma

India
IPPE
Not Confirmed
arrow

Scinvapharma

India
IPPE
Not Confirmed
arrow

CAS Number : 439089-27-7

End Use API : Elobixibat

About The Company : Scinva is a startup dedicated to offering high-quality products and services, providing a comprehensive range of services from custom synthesis to the trade of ...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : Goofice

Elobixibat

arrow
HPCI India
Not Confirmed

Brand Name : Goofice

Japan
arrow
HPCI India
Not Confirmed

Elobixibat

Main Therapeutic Indication : Gastrointestinal Disorders

Currency : USD

2021 Revenue in Millions : 8

2020 Revenue in Millions : 0

Growth (%) : 100

blank

02

Brand Name : Goofice

Elobixibat

arrow
HPCI India
Not Confirmed

Brand Name : Goofice

Japan
arrow
HPCI India
Not Confirmed

Elobixibat

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2022 Revenue in Millions : 11

2021 Revenue in Millions : 8

Growth (%) : 50

blank

03

Brand Name : Goofice

Elobixibat

arrow
HPCI India
Not Confirmed

Brand Name : Goofice

Japan
arrow
HPCI India
Not Confirmed

Elobixibat

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2023 Revenue in Millions : 38

2022 Revenue in Millions : 50

Growth (%) : -14

blank

04

Brand Name : Goofice

Elobixibat

arrow
HPCI India
Not Confirmed

Brand Name : Goofice

Japan
arrow
HPCI India
Not Confirmed

Elobixibat

Main Therapeutic Indication : Gastrointestinal Diseases

Currency : USD

2024 Revenue in Millions : 49

2023 Revenue in Millions : 53

Growth (%) : -8

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for 439087-18-0 / Elobixibat API manufacturers, exporters & distributors?

Elobixibat manufacturers, exporters & distributors 1

77

PharmaCompass offers a list of Elobixibat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Elobixibat manufacturer or Elobixibat supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Elobixibat manufacturer or Elobixibat supplier.

PharmaCompass also assists you with knowing the Elobixibat API Price utilized in the formulation of products. Elobixibat API Price is not always fixed or binding as the Elobixibat Price is obtained through a variety of data sources. The Elobixibat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Elobixibat

Synonyms

439087-18-0, Azd7806, Azd-7806, 865uek4ejc, A-3309, Glycine, (2r)-n-(2-((3,3-dibutyl-2,3,4,5-tetrahydro-7-(methylthio)-1,1-dioxido-5-phenyl-1,5-benzothiazepin-8-yl)oxy)acetyl)-2-phenylglycyl-

Cas Number

439087-18-0

Unique Ingredient Identifier (UNII)

865UEK4EJC

About Elobixibat

Elobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation.

Elobixibat Manufacturers

A Elobixibat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Elobixibat, including repackagers and relabelers. The FDA regulates Elobixibat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Elobixibat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Elobixibat manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Elobixibat Suppliers

A Elobixibat supplier is an individual or a company that provides Elobixibat active pharmaceutical ingredient (API) or Elobixibat finished formulations upon request. The Elobixibat suppliers may include Elobixibat API manufacturers, exporters, distributors and traders.

click here to find a list of Elobixibat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Elobixibat USDMF

A Elobixibat DMF (Drug Master File) is a document detailing the whole manufacturing process of Elobixibat active pharmaceutical ingredient (API) in detail. Different forms of Elobixibat DMFs exist exist since differing nations have different regulations, such as Elobixibat USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Elobixibat DMF submitted to regulatory agencies in the US is known as a USDMF. Elobixibat USDMF includes data on Elobixibat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Elobixibat USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Elobixibat suppliers with USDMF on PharmaCompass.

Elobixibat NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Elobixibat as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Elobixibat API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Elobixibat as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Elobixibat and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Elobixibat NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Elobixibat suppliers with NDC on PharmaCompass.

Elobixibat GMP

Elobixibat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Elobixibat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Elobixibat GMP manufacturer or Elobixibat GMP API supplier for your needs.

Elobixibat CoA

A Elobixibat CoA (Certificate of Analysis) is a formal document that attests to Elobixibat's compliance with Elobixibat specifications and serves as a tool for batch-level quality control.

Elobixibat CoA mostly includes findings from lab analyses of a specific batch. For each Elobixibat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Elobixibat may be tested according to a variety of international standards, such as European Pharmacopoeia (Elobixibat EP), Elobixibat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Elobixibat USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty